GlassScriptPhysician profile
Charles W Callender
NPI 1972576320
$20,476.87
in general payments reported to CMS, 2019-2025
52 companies · $3,514 in 2025
The $3,514 reported for 2025 was more than what 85% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $315 · 2020: $116 · 2021: $98.49 · 2022: $6,581 · 2023: $6,688 · 2024: $3,164 · 2025: $3,514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Consulting Fee: $2,183 · Travel and Lodging: $906 · Grant: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,177.88 |
| Consulting Fee | $2,183.46 |
| Travel and Lodging | $905.63 |
| Grant | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $4,529.64 | 2022-2025 | |
| Intuitive Surgical, INC. | $3,317.41 | 2022-2025 | |
| Glaxosmithkline, LLC. | $2,011.16 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,871.98 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Grifols USA, LLC | $1,064.56 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Regeneron Healthcare Solutions, INC. | $1,007.38 | 2022-2025 | Dupixent |
| Insmed, INC. | $612.63 | 2021-2025 | Arikayce, Brinsupri |
| Mallinckrodt Hospital Products INC. | $569.33 | 2021-2025 | Acthar, Terlivaz |
| Inspire Medical Systems, INC. | $567.24 | 2023-2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $489.57 | 2019-2025 | Ofev, Stiolto Respimat |
| Amgen INC. | $361.06 | 2022-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $291.78 | 2022-2025 | Cuvitru, Hyqvia, Glassia |
| Mylan Specialty L.P. | $279.10 | 2021-2024 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $273.12 | 2019-2025 | Opsumit, Uptravi |
| United Therapeutics Corporation | $249.96 | 2019-2025 | Tyvaso, Tyvaso |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $215.53 | 2022-2023 | Ultomiris |
| Csl Behring | $214.81 | 2022-2024 | Hizentra, Kcentra |
| Verona Pharma, INC. | $203.98 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $189.28 | 2019-2025 | Winrevair |
| Philips North America LLC | $173.72 | 2023-2024 | (Ak6) Vest Therapy |
| Novartis Pharmaceuticals Corporation | $160.67 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $138.68 | 2022-2024 | |
| La Jolla Pharmaceutical Company | $136.40 | 2022-2025 | Giapreza |
| Abbvie INC. | $132.97 | 2024-2025 | |
| Regeneron Pharmaceuticals, INC. | $126.70 | 2022 | |
| Pulmonx Corporation | $107.65 | 2019-2025 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Electromed, INC. | $102.62 | 2022-2025 | Smartvest |
| Ani Pharmaceuticals, INC. | $88.32 | 2023-2024 | Purified Cortrophin Gel |
| Baxter Healthcare | $87.64 | 2022-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Allergan, INC. | $75.29 | 2019-2020 | |
| Inogen, INC. | $74.64 | 2023-2024 | Inogen |
| Viatris Specialty LLC | $69.45 | 2025 | Yupelri |
| Octapharma USA, INC. | $64.68 | 2020 | |
| Idorsia Pharmaceuticals US INC | $61.26 | 2023 | Quviviq |
| Jazz Pharmaceuticals INC. | $60.35 | 2020-2023 | Xywav |
| Vifor Pharma, INC. | $57.78 | 2024 | Zemaira, Veltassa |
| Pfizer INC. | $53.78 | 2025 | |
| Axsome Therapeutics, INC. | $52.27 | 2024-2025 | Sunosi |
| Tempus Ai, INC | $49.09 | 2025 | Xt Cdx |
| Harmony Biosciences LLC | $41.67 | 2025 | |
| Tactile Systems Technology INC | $28.77 | 2025 | Nimbl, Flexitouch Plus |
| Ambu INC. | $24.73 | 2023 | |
| Sanofi-Aventis U.S. LLC | $23.83 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $21.52 | 2025 | Camzyos |
| Sanofi Pasteur INC. | $20.59 | 2025 | |
| Shionogi INC | $20.55 | 2025 | Fetroja |
| Avadel Cns Pharmaceuticals, LLC | $19.32 | 2025 | Lumryz |
| Advanced Respiratory, INC | $18.47 | 2019 | |
| Adma Biomanufacturing LLC | $18.46 | 2024 | |
| Paratek Pharmaceuticals, INC. | $17.49 | 2025 | Nuzyra |
| Covidien LP | $14.02 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Callender listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.